NAGly

NAGly, also known as N-arachidonoyl glycine, is a molecule that is part of the endocannabinoid system. It is a metabolite of the endocannabinoid anandamide (AEA), and is produced in the body through the oxidation of AEA by the enzyme fatty acid amide hydrolase (FAAH). NAGly has been found to have several biological effects, including anti-inflammatory and analgesic properties.

Structure and Synthesis[edit | edit source]

NAGly is a fatty acid amide, consisting of a fatty acid (arachidonic acid) and an amino acid (glycine) joined together by an amide bond. It is synthesized in the body from anandamide, a naturally occurring endocannabinoid, through the action of the enzyme FAAH. This enzyme oxidizes anandamide, removing a hydrogen atom and adding an oxygen atom to form NAGly.

Biological Effects[edit | edit source]

NAGly has been found to have several biological effects. It has anti-inflammatory properties, and has been shown to reduce pain in animal models. It also has neuroprotective effects, and may play a role in the regulation of sleep and appetite.

NAGly acts on several different types of receptors in the body. It is a partial agonist of the CB1 receptor and the CB2 receptor, which are the main receptors of the endocannabinoid system. It also acts on the GPR18 receptor, and may act on other receptors as well.

Research and Potential Therapeutic Uses[edit | edit source]

Research into NAGly is ongoing, and it is thought to have potential therapeutic uses. Its anti-inflammatory and analgesic properties suggest that it could be used to treat conditions such as chronic pain and inflammatory diseases. Its neuroprotective effects suggest that it could be used to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

See Also[edit | edit source]

NAGly Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.